4YD Stock Chart & Stats
€0.04
<€0.01(1.49%)
At close: 4:00 PM EST
€0.04
<€0.01(1.49%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.13
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€10.94M
Enterprise Value€176.85
Total Cash (Recent Filing)€19.06M
Total Debt (Recent Filing)€53.63M
Price to Earnings (P/E)1.1
Beta14.42
Next Earnings
Nov 26, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.35
Shares Outstanding328,769,840
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)3.04
Price to Sales (P/S)3.26
P/FCF Ratio-1.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)€12.97M
Bulls Say, Bears Say
Bulls Say
Accelerating RevenueRapid TTM revenue growth indicates improving commercial traction and suggests that Nanologica is gaining adoption for its offerings. If this momentum continues through customer expansion and scale-up, it can provide a stronger base for operating leverage and future investment in the business.
Improved Balance SheetThe stronger equity position and moderate leverage provide a more resilient financial foundation than in prior years. Lower relative debt pressure can preserve flexibility for capacity investment and help the company manage its development cycle while it works toward sustainable operating profitability.
Specialized Pharma ApplicationsNanologica operates in specialized life-science workflows where its engineered silica materials address purification, separation, and formulation needs. Exposure to drug development and production gives the business a defined technical focus and potential relevance across recurring pharmaceutical processes.
Bears Say
Persistent Operating LossesDeeply negative gross and operating profit show that revenue growth has not yet translated into a sustainable operating model. Continued losses can limit reinvestment capacity and indicate that pricing, production economics, or the cost base must improve before growth produces durable earnings.
Ongoing Cash BurnNegative operating and free cash flow means the company is not currently self-funding its operations and investment needs. Persistent cash burn can increase reliance on external financing and constrain strategic flexibility until customer receipts, margins, and working-capital conversion improve.
Balance Sheet InstabilityAlthough the current capital base is stronger, the history of very low or negative equity shows that financial resilience has been unstable. A recurrence of operating losses or cash needs could require further recapitalization, potentially diluting shareholders and limiting long-term flexibility.
Nanologica AB News
4YD FAQ
What was Nanologica AB’s price range in the past 12 months?
Nanologica AB lowest stock price was <€0.01 and its highest was €0.13 in the past 12 months.
What is Nanologica AB’s market cap?
Nanologica AB’s market cap is €10.94M.
When is Nanologica AB’s upcoming earnings report date?
Nanologica AB’s upcoming earnings report date is Nov 26, 2026 which is in 81 days.
How were Nanologica AB’s earnings last quarter?
Nanologica AB released its earnings results on Aug 31, 2026. The company reported -€0.005 earnings per share for the quarter.
Is Nanologica AB overvalued?
According to Wall Street analysts Nanologica AB’s price is currently Overvalued.
Does Nanologica AB pay dividends?
Nanologica AB does not currently pay dividends.
What is Nanologica AB’s EPS estimate?
Nanologica AB’s EPS estimate is >-0.01.
How many shares outstanding does Nanologica AB have?
Nanologica AB has 328,769,840 shares outstanding.
What happened to Nanologica AB’s price movement after its last earnings report?
Nanologica AB reported an EPS of -€0.005 in its last earnings report. Following the earnings report the stock price went up 6.452%.
Which hedge fund is a major shareholder of Nanologica AB?
Currently, no hedge funds are holding shares in DE:4YD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nanologica AB
Nanologica AB (publ), a nanotechnology company, develops, manufactures, and sells nanoporous silica particles for life science industry in China, India, the United State of America, and internationally. It offers NLAB Saga, a new generation silica for preparative chromatography; and SVEA, a pre-packaged columns for analytical chromatography; and high-performance liquid chromatography, a separation method based on different substances in a solution passing through a column at different paces. The company provides products for the analysis and purification of substances, with a focus on peptides drugs for the treatment of diabetes and obesity. Nanologica AB (publ) was incorporated in 2004 and is headquartered in Södertälje, Sweden.
Technical Analysis
Camurus AB
―
Xbrane Biopharma AB
―
Xspray Pharma AB
―
Spago Nanomedical AB
―
Nanexa AB
―